Minerva Neurosciences | NERV - Net Income


Minerva Neurosciences reported $1.44M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Adma Biologics USD 45.33M 4.05M Mar/2026
ALKERMES USD 501K 66.98M Jun/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
AstraZeneca USD 2.51B 573M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Cipla INR 7.89B 2.34B Jun/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.67M 64.51M Mar/2026
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
J&J USD 210M 5.32B Sep/2026
Merck USD -1.34B 2.9B Jun/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -248M 2.94B Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Takeda JPY 113.2B 137.52B Jun/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024